Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Madrigal Pharmaceuticals Inc is a biotechnology business based in the US. Madrigal Pharmaceuticals shares (MDGL) are listed on the NASDAQ and all prices are listed in US Dollars. Madrigal Pharmaceuticals employs 71 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $71.58 |
|---|---|
| 52-week range | $52.33 - $105.93 |
| 50-day moving average | $70.58 |
| 200-day moving average | $80.20 |
| Wall St. target price | $160.58 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-14.65 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $71.58 from 2022-06-30
| 1 week (2022-06-24) | -14.23% |
|---|---|
| 1 month (2022-06-01) | 8.36% |
| 3 months (2022-04-01) | -28.56% |
| 6 months (2021-12-29) | -13.19% |
| 1 year (2021-07-01) | -27.97% |
|---|---|
| 2 years (2020-07-01) | -36.23% |
| 3 years (2019-07-01) | 106.53 |
| 5 years (2017-06-30) | 340.22% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -58.01% |
| Return on equity TTM | -121.5% |
| Profit margin | 0% |
| Book value | $8.52 |
| Market capitalisation | $1.5 billion |
TTM: trailing 12 months
We're not expecting Madrigal Pharmaceuticals to pay a dividend over the next 12 months.
Madrigal Pharmaceuticals's shares were split on a 1:35 basis on 24 July 2016. So if you had owned 35 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Madrigal Pharmaceuticals shares – just the quantity. However, indirectly, the new 3400% higher share price could have impacted the market appetite for Madrigal Pharmaceuticals shares which in turn could have impacted Madrigal Pharmaceuticals's share price.
Over the last 12 months, Madrigal Pharmaceuticals's shares have ranged in value from as little as $52.33 up to $105.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Madrigal Pharmaceuticals's is 1.2827. This would suggest that Madrigal Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Madrigal Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.